Harrow Inc (HROW)

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient...

Form 8-K - Current report

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights:  VEVYE® delivered record new and total prescription performance...

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic...